Leukemia Research
Volume 34, Issue 4 , Pages 411-412 , April 2010

Captivating Bortezomib: An active but still mysterious drug

  • Francesco Di Raimondo

      Affiliations

    • Divisione Clinicizzata di Ematologia, Universita degli Studi di Catania, Ospedale Ferrarotto, Via Citelli, 6 Catania, 95124, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 095 7435968; fax: +39 095 365174.
    • ,
  • Concetta Conticello

      Affiliations

    • Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM),Viagrande, Catania Italy

Received 20 August 2009

References 

  1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324–339
  2. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18 Pt 1):5291–5294
  3. Matondo M, Bousquet-Dubouch MP, Uttenweiler S, Recher C, Payrastre B, Manenti S, et al. Differentiation-dependent apoptosis induced by proteasome inhibitors in acute myeloid leukemia: a correlation with the proteasome status. Leuk Res.
  4. Conticello C, Adamo L, Vicari L, Giuffrida R, Iannolo G, Anastasi G, et al. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol. 2008;120:19–30
  5. Attar EC, De Angelo DJ, Supko JG, D’Amato F, Zahrieh D, Sirulnik A, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446–1547
  6. Vink J, Cloos J, Kaspers GJ. Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol. 2006;134:253–262
  7. Gilel FJ. New drugs in acute myeloid leukemia. Curr Oncol Rep. 2002;4(5):369–374
  8. Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G, et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Haematol. 2007;139(2):194–205
  9. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961–2969
  10. Zhao X, Qiu W, Kung J, Peng X, Yegappan M, Yen-Lieberman B, et al. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008;32:275–285
  11. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood. 2006;107:1731–1732
  12. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;10;277(19):16639–16647
  13. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114:1046–1052
  14. Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, et al. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des. 2007;13:471–485
  15. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278:33714–33723
  16. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282–6293

PII: S0145-2126(09)00481-0

doi: 10.1016/j.leukres.2009.09.021

Leukemia Research
Volume 34, Issue 4 , Pages 411-412 , April 2010

Article Tools